Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

Article  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23(3):382–92.

Article  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(6):691–722.

Article  Google Scholar 

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.

Article  PubMed  Google Scholar 

Sella T, Ruddy KJ, Carey LA, Partridge AH. Optimal endocrine therapy in premenopausal women: a pragmatic approach to unanswered questions. JCO Oncol Pract. 2021. https://doi.org/10.1200/OP.21.00482.

Article  PubMed  Google Scholar 

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–38.

Article  CAS  PubMed  Google Scholar 

Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol. 2023;41(7):1376–82.

Article  CAS  PubMed  Google Scholar 

Kim ES. Abemaciclib: first global approval. Drugs. 2017;77(18):2063–70.

Article  PubMed  Google Scholar 

Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. JCO. 2001;19(2):322–8.

Article  CAS  Google Scholar 

Arimidex, Tamoxifen, Alone or in Combination Trialists’ Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633–43.

Article  PubMed  Google Scholar 

Collin LJ, Cronin-Fenton DP, Ahern TP, Goodman M, McCullough LE, Waller LA, et al. Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women. Clin Cancer Res. 2021;27(5):1421–8.

Article  PubMed  Google Scholar 

Yussof I, Mohd Tahir NA, Hatah E, Mohamed SN. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. Breast. 2022;62:22–35.

Article  PubMed  PubMed Central  Google Scholar 

Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.

Article  PubMed  PubMed Central  Google Scholar 

Lambert-Côté L, Bouhnik AD, Bendiane MK, Bérenger C, Mondor M, Huiart L, et al. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. Breast Cancer Res Treat. 2020;180(3):777–90.

Article  PubMed  Google Scholar 

Lailler G, Memoli V, Le Bihan BC, Ben Diane MK, Lauzier S, Mancini J, et al. Five-year adjuvant endocrine therapy adherence trajectories among women with breast cancer: a nationwide French study using administrative data. Clin Breast Cancer. 2021;21(4):e415–26.

Article  CAS  PubMed  Google Scholar 

Tervonen HE, Daniels B, Tang M, Preen DB, Pearson SA. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients. Pharmacoepidemiol Drug Saf. 2019;28(6):812–20.

Article  CAS  PubMed  Google Scholar 

Franklin JM, Shrank WH, Pakes J, Sanfélix-Gimeno G, Matlin OS, Brennan TA, et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789–96.

Article  PubMed  Google Scholar 

Nagin DS. Group-based trajectory modeling: an overview. ANM. 2014;65(2–3):205–10.

CAS  Google Scholar 

Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–38.

Article  PubMed  Google Scholar 

Hawley CE, Lauffenburger JC, Paik JM, Wexler DJ, Kim SC, Patorno E. Three sides to the story: adherence trajectories during the first year of SGLT2 inhibitor therapy among medicare beneficiaries. Diabetes Care. 2022;45(3):604–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf. 2016;25(8):953–9.

Article  CAS  PubMed  Google Scholar 

Collin LJ, Cronin-Fenton DP, Ahern TP, Christiansen PM, Damkier P, Ejlertsen B, et al. Cohort profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) premenopausal breast cancer cohort study in Denmark. BMJ Open. 2018;8(7): e021805.

Article  PubMed  PubMed Central  Google Scholar 

Jensen MB, Laenkholm AV, Offersen BV, Christiansen P, Kroman N, Mouridsen HT, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. Acta Oncol. 2018;57(1):13–8.

Article  PubMed  Google Scholar 

Christiansen P, Ejlertsen B, Jensen MB, Mouridsen H. Danish Breast Cancer Cooperative Group. Clin Epidemiol. 2016;25(8):445–9.

Article  Google Scholar 

Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798–798f.

PubMed  Google Scholar 

Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;20(7):35–44.

Google Scholar 

Jones B, Nagin D. Proc TRAJ: A SAS procedure for group-based modeling of longitudinal data. In 2007.

Librero J, Sanfélix-Gimeno G, Peiró S. Medication adherence patterns after hospitalization for coronary heart disease. A population-based study using electronic records and group-based trajectory models. PLoS ONE. 2016;11(8):e0161381.

Article  PubMed  PubMed Central  Google Scholar 

Hickson RP, Annis IE, Killeya-Jones LA, Fang G. Opening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: an example using real-world statin adherence data. Pharmacoepidemiol Drug Saf. 2020;29(3):357–62.

Article  PubMed  Google Scholar 

Hargrove JL, Pate V, Casteel CH, Golightly YM, Loehr LR, Marshall SW, et al. Antihypertensive adherence trajectories among older adults in the first year after initiation of therapy. Am J Hypertens. 2017;30(10):1015–23.

Article  PubMed  PubMed Central  Google Scholar 

Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7 Suppl):103–5.

Article  PubMed  Google Scholar 

Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39(7_suppl):91–4.

Article  PubMed  Google Scholar 

Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–9.

Article  PubMed  Google Scholar 

Buuren S van, Groothuis-Oudshoorn K, Vink G, Schouten R, Robitzsch A, Rockenschaub P, et al. mice: multivariate imputation by chained equations [Internet]. 2022 [cited 2023 May 4]. Available from https://cran.r-project.org/web/packages/mice/index.html.

Bright EE, Finkelstein LB, Nealis MS, Genung SR, Wrigley J, Gu HCJ, et al. A systematic review and meta-analysis of interventions to promote adjuvant endocrine therapy adherence among breast cancer survivors. J Clin Oncol. 2023. https://doi.org/10.1200/JCO.23.00697?role=tab.

Article  PubMed  Google Scholar 

Schapira L, Zheng Y, Gelber SI, Poorvu P, Ruddy KJ, Tamimi RM, et al. Trajectories of fear of cancer recurrence in young breast cancer survivors. Cancer. 2022;128(2):335–43.

Article  PubMed  Google Scholar 

Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, et al. The incidence of breast cancer recurrence 10-32 years after primary diagnosis. JNCI: J Natl Cancer Inst. 2022;114(3):391–9.

Article  PubMed  Google Scholar 

Haskins CB, McDowell BD, Carnahan RM, Fiedorowicz JG, Wallace RB, Smith BJ, et al. Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat. 2019;174(1):197–208.

Article  CAS  PubMed  Google Scholar 

Schmidt M, Schmidt SAJ, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–91.

Article  PubMed  PubMed Central  Google Scholar 

Ma S, Shepard DS, Ritter GA, Martell RE, Thomas CP. Cost sharing for breast cancer hormone therapy: how do dual eligible patients’ copayment impact adherence. PLoS ONE. 2021;16(5): e0250967.

Article